AU2022316644A1 - Medicament for treatment and/or prevention of cancer - Google Patents

Medicament for treatment and/or prevention of cancer Download PDF

Info

Publication number
AU2022316644A1
AU2022316644A1 AU2022316644A AU2022316644A AU2022316644A1 AU 2022316644 A1 AU2022316644 A1 AU 2022316644A1 AU 2022316644 A AU2022316644 A AU 2022316644A AU 2022316644 A AU2022316644 A AU 2022316644A AU 2022316644 A1 AU2022316644 A1 AU 2022316644A1
Authority
AU
Australia
Prior art keywords
seq
variable region
chain variable
amino acid
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022316644A
Other languages
English (en)
Inventor
Masahiko Kume
Fumiyoshi Okano
Takanori Saito
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Toray Industries Inc
Original Assignee
Toray Industries Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Toray Industries Inc filed Critical Toray Industries Inc
Publication of AU2022316644A1 publication Critical patent/AU2022316644A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
AU2022316644A 2021-07-27 2022-07-27 Medicament for treatment and/or prevention of cancer Pending AU2022316644A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-122071 2021-07-27
JP2021122071 2021-07-27
PCT/JP2022/028877 WO2023008461A1 (ja) 2021-07-27 2022-07-27 癌の治療及び／又は予防のための医薬品

Publications (1)

Publication Number Publication Date
AU2022316644A1 true AU2022316644A1 (en) 2024-02-29

Family

ID=85087718

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022316644A Pending AU2022316644A1 (en) 2021-07-27 2022-07-27 Medicament for treatment and/or prevention of cancer

Country Status (8)

Country Link
EP (1) EP4378477A4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JPWO2023008461A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR20240042415A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN117651566A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (1) AU2022316644A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA3227703A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX2024001099A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2023008461A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
SK14812000A3 (sk) 1998-04-03 2001-08-06 Chugai Seiyaku Kabushiki Kaisha Chimérny reťazec protilátky, chimérna protilátka, v oblasť, humanizovaný reťazec protilátky, humanizovaná protilátka, dna, expresný vektor, hostiteľ, spôsob prípravy a liečivo
WO1999054342A1 (en) 1998-04-20 1999-10-28 Pablo Umana Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
EP3031917A1 (en) 1999-04-09 2016-06-15 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
JP2006524039A (ja) 2003-01-09 2006-10-26 マクロジェニクス，インコーポレーテッド 変異型Ｆｃ領域を含む抗体の同定および作製ならびにその利用法
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
DE10359795A1 (de) 2003-12-19 2005-07-21 Bayer Technology Services Gmbh Strangverdampfervorrichtung
DK2322221T3 (da) 2008-08-05 2014-09-01 Toray Industries Farmaceutisk sammensætning til behandling og forebyggelse af cancer
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
AU2011211682B2 (en) 2010-02-04 2015-08-13 Toray Industries, Inc. Pharmaceutical composition for treating and/or preventing cancer
KR101801667B1 (ko) 2010-02-04 2017-11-27 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
PT2532743E (pt) 2010-02-04 2015-08-04 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção de cancro
KR101842893B1 (ko) 2010-02-04 2018-03-28 도레이 카부시키가이샤 암의 치료 및/또는 예방용 의약 조성물
MX2012008991A (es) 2010-02-04 2012-09-07 Toray Industries Medicamento para tratar y/o prevenir el cancer.
JP5845899B2 (ja) 2010-02-04 2016-01-20 東レ株式会社 癌の治療及び／又は予防用医薬組成物
CA2794708C (en) 2010-03-29 2021-11-16 Zymeworks Inc. Antibodies with enhanced or suppressed effector function
HUE033183T2 (en) 2011-08-04 2017-11-28 Toray Industries A medicament for treating and / or preventing cancer
HUE047006T2 (hu) 2011-08-04 2020-04-28 Toray Industries Anti-caprin-1 antitesteket tartalmazó gyógyászati kompozíció rák kezelésére és/vagy megelõzésére
CA2844040C (en) 2011-08-04 2019-05-07 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prophylaxis of cancer
PT2740489T (pt) 2011-08-04 2017-01-10 Toray Industries Composição farmacêutica para o tratamento e/ou a prevenção do cancro pancreático
MX348579B (es) 2011-08-04 2017-06-20 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
DK2740795T3 (en) 2011-08-04 2017-01-16 Toray Industries Pharmaceutical composition for the treatment and / or prevention of cancer
WO2013125636A1 (ja) 2012-02-21 2013-08-29 東レ株式会社 癌の治療及び／又は予防用医薬組成物
HUE045461T2 (hu) 2012-02-21 2019-12-30 Toray Industries Gyógyászati készítmény rák kezelésére
AU2013223161B2 (en) 2012-02-21 2017-10-19 Toray Industries, Inc. Medicinal composition for treating and/or preventing cancer
CN104114581B (zh) 2012-02-21 2018-11-30 东丽株式会社 癌的治疗和/或预防用药物组合物
PL2832365T3 (pl) 2012-03-30 2018-04-30 Toray Industries, Inc. Kompozycja farmaceutyczna do leczenia i/lub zapobiegania nowotworowi wątroby
ES2656501T3 (es) 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención de cáncer de vesícula biliar
CN112587671A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
MX360671B (es) 2013-08-09 2018-11-13 Toray Industries Composición farmacéutica para el tratamiento y/o prevención del cáncer.
US10593576B2 (en) 2015-03-03 2020-03-17 Brooks Automation (Germany) Gmbh Inspection system
MX2020009862A (es) * 2018-03-30 2020-10-08 Toray Industries Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
EP4119156A4 (en) * 2020-03-12 2024-05-08 Toray Industries, Inc. MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER

Also Published As

Publication number Publication date
WO2023008461A1 (ja) 2023-02-02
EP4378477A4 (en) 2025-08-13
JPWO2023008461A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2023-02-02
MX2024001099A (es) 2024-02-23
KR20240042415A (ko) 2024-04-02
CN117651566A (zh) 2024-03-05
CA3227703A1 (en) 2023-02-02
EP4378477A1 (en) 2024-06-05

Similar Documents

Publication Publication Date Title
AU2024266817A1 (en) B cell maturation antigen binding proteins
AU2022204340B2 (en) Human immunodeficiency virus neutralising antibodies and methods of use thereof
AU2023208064A1 (en) Mesothelin binding proteins
AU2025204722A1 (en) Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
AU2023204219A1 (en) Anti-claudin 18.2 antibodies and uses thereof
AU2024202894A1 (en) Anti-respiratory syncytial virus antibodies, methods of their generation and use
AU2025204039A1 (en) Muscle targeting complexes and uses thereof for treating myotonic dystrophy
AU2025203336A1 (en) Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
AU2025203767A1 (en) Manabodies And Methods Of Using
AU2024278257A1 (en) Methods of treating inflammatory conditions
AU2024200553A1 (en) T cell recruiting polypeptides based on TCR alpha/beta reactivity
AU2024266712A1 (en) Antibodies for siglec-15 and methods of use thereof
AU2024204502A1 (en) Anti-her3 antibody-drug conjugate
AU2023219928A1 (en) Chimeric antigen receptors targeting B-cell maturation antigen
AU2023233053A1 (en) Chimeric antigen receptors and CAR-T cells and methods of use
AU2025204808A1 (en) Binding agents
AU2024219621A1 (en) Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
AU2025203121A1 (en) Clec9A binding agents and use thereof
AU2024227695A1 (en) T cell receptors recognizing mutated p53
AU2025200120A1 (en) Anti-BTLA antibodies
AU2025202702A1 (en) Methods of treating cancer using antibodies and molecules that immunospecifically bind to BTN1A1
AU2025201828A1 (en) Anti-lilrb1 antibody and uses thereof
AU2023265269A1 (en) Anti-CD300c antibody or antigen-binding fragment thereof and use thereof for preventing or treating degenerative brain disease
AU2025200303A1 (en) Polypeptides that bind complement component c5 or serum albumin and fusion proteins thereof
AU2023298568A1 (en) Pharmaceutical composition for cancer treatment and/or prevention